|
synovial sarcoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
SS treated A431 and SAS cells showed upregulation of p53 and dysregulation of Bax and Bcl-2 gene expression.
|
30391273 |
2019 |
|
synovial sarcoma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Quisinostat inhibits aggresome formation in response to proteasome inhibition, and combination treatment leads to elevated endoplasmic reticulum stress, activation of pro-apoptotic effector proteins BIM and BIK, phosphorylation of BCL-2, increased levels of reactive oxygen species, and suppression of tumor growth in a murine model of synovial sarcoma.
|
28056055 |
2017 |
|
synovial sarcoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Thus, the contributory role of BCL2 in synovial sarcomagenesis does not appear to render it as a therapeutic target, but mitochondrial antiapoptotic BCL2 family members may be.<b>Implications:</b> The association of BCL2 expression with synovial sarcoma is found to fit with a subtle, but significant, impact of its enhanced presence or absence during early tumorigenesis.
|
28851813 |
2017 |
|
synovial sarcoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Forty monophasic spindle cell type (58.8%), 13 biphasic (19.1%), 12 poorly differentiated (17.6%) and three calcifying SSs (4.4%) were positive for epithelial membrane antigen (EMA) (46/62) (74.1%), pan cytokeratin (AE1/AE3) (31/47) (65.9%), cytokeratin (CK7) (20/31) (64.5%), BCL2 (62/66) (93.9%), MIC2 (61/63) (96.8%), transducin-like enhancer of split 1 (TLE1) (29/31) (93.5%) and CK19 (14/24) (58.3%).
|
25912315 |
2015 |
|
synovial sarcoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Elevated expression of BCL2 is considered a consistent feature of the synovial sarcoma expression profile.
|
22797074 |
2013 |
|
synovial sarcoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
A large necrotic tumour positive for CK 22, EMA, CD 99 and BCL-2 but negative for translocation in COBRA-FISH analysis by break-apart probe could be excised and revealed a very rare subtype of synovial sarcoma metastasis arising from the endocard of the left atrium.
|
21425056 |
2012 |
|
synovial sarcoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Treatment with antisense BCL2 (G3139) may therefore represent an appropriate alternative therapy for patients with BCL2-positive synovial sarcomas.
|
19602458 |
2009 |
|
synovial sarcoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In summary, avicin D selectively induced apoptosis, inhibited STAT-3 activation, and decreased apoptosis inhibitors (bcl-2 and survivin) in CTCL cell lines and SS patients' Sézary cells.
|
18496567 |
2008 |
|
synovial sarcoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Treatment of FU-SY-1 SS with G3139 reduced Bcl-2 mRNA and protein levels, which enhanced doxorubicin-induced cell killing.
|
16450387 |
2006 |
|
synovial sarcoma
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Treatment of FU-SY-1 SS with G3139 reduced Bcl-2 mRNA and protein levels, which enhanced doxorubicin-induced cell killing.
|
16450387 |
2006 |
|
synovial sarcoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The SYT-SSX fusion protein that results from the X,18 translocation is an appealing target, as are the proteins overexpressed in synovial sarcoma: bcl-2, EGFR, and HER-2/neu.
|
15838395 |
2005 |
|
synovial sarcoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Most SS were strongly positive for bcl-2 (91% of MFSS, 92% of PDSS) and CD99 (91% of MFSS, 100% of PDSS).
|
12409719 |
2002 |
|
synovial sarcoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Synovial sarcoma had a significantly higher expression of Bcl-2 protein, and lower incidence of apoptosis.
|
11867201 |
2002 |
|
synovial sarcoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Four of 19 synovial sarcomas (21%) demonstrated nuclear over-expression of p53 protein; 18 of 19 tumors (94%) stained positive for Bcl-2; and 13 of 19 tumors (68%) were immunoreactive with EGFR.
|
12458341 |
2002 |
|
synovial sarcoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Interestingly, whereas bcl2 over-expression appears to be restricted to the spindle cell tumoral component, c-kit mainly involves the epithelial component of biphasic SS.
|
11487273 |
2001 |
|
synovial sarcoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In addition to these cytogenetic changes, bcl-2 expression, as assessed by immunohistochemistry, has been reported to be an almost general constitutive alteration of SS.
|
10879732 |
2000 |